Keeping in mind that BCL2 is a therapeutic target in CLL (57), this system might potentially be more reliable in predicting responses in patients and also to understand how cells may adapt to the presence of the drug with time, when cultured in a more protective microenvironment. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.